Epidemiology of the Age-Related Macular Degeneration

Czech version

Authors: P. Kolář
Authors‘ workplace: Oční klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice, Brno, přednostka prof. MUDr. Eva Vlková, CSc.
Published in: Čes. a slov. Oftal., 66, 2010, No. 3, p. 127-130

Overview

The age-related macular degeneration is the most common cause of severe decrease of the visual acuity in industrial countries. The epidemiological data published in last 30 years are very alarming. They document that the age-related macular degeneration is the most common cause of blindness in industrial countries in the population of patients older than 65 years. The signs of beginning disease may be diagnosed as early as in the patients older than 45 years. The disease is strictly age-related and its prevalence and incidence is markedly increasing according to the older age. The basic risk factors of the disease are smoking, untreated hypertension, atherosclerosis, cataract surgery, and appearance of the disease in the family. Among further possible risk factors we count diabetes mellitus and the light color of the iris. Equivocal is the negative influence of ultraviolet rays.

Key words:
age-related macular degeneration, prevalence, incidence, Beaver Dam Study, Blue Mountain Study, Rotterdam Study, Pola Study

Sources

1. Bjornsson, O., M., Kinge, B., Syrdalen, P., et al.: The prevalence of age-related maculopathy (ARM) in an urban Norwegian population-Oslo Macular study. Invest Ophthalmol Vis Sci, 2003; 44: 3082.

2. Delcourt, C., Lacroux, A., CarriŹre, I., et al.: The Three-Year Incidence of Age- Related Macular Degeneration: The “Pathologies Oculaires Liées ą l’Age” (POLA) Prospective Study. Am J Ophthalmol, 2005; 140: 924–926.

3. Fryczkowski, A., W., Sato, S., E., Hodes, B., L.: Changes in the diabetic choroidal vasculature: Scanning electron micros- copy findings. Ann Ophthalmol 1988; 20: 299 –305.

4. Gass, J., D.: Drusen and disciform macular detachment and degeneration. Arch Ophthalmol, 1973; 90: 206 –217.

5. Holtz, F., G., Piguet, B., Minassian, D., C., Bird, A., C. et al.: Decreasing stromal iris pigmentation as a risk factor of age-related macular degeneration. Am J Ophthalmol, 1994; 117:19–23.

6. Jampol, L., M., Tielsch, J.: Race, macular degeneration, and the Macular Photocoagulation study. Arch Ophthalmol, 1992; 110: 1699 –1700.

7. Jonasson, F., Arnarsson, A., Sverisson, T, et al.: 5-year incidence of age-related maculopathy-Reykjavik Eye study. Invest Ophthalmol Vis Sci 2003; 44: 3083

8. Klaver, C., C., Wolfs, R., C., Assink, J., J.: Genetic risk of age-related maculopathy: Population-based familial aggregate study. Arch Ophthalmol 1998; 116: 1646–1651.

9. Klein, R., Klein, B., E., Cruickshanks, K., J.: The prevalence of age-related maculopathy by geographic region and ethnicity. Prog Retin Eye Res, 1999; 18: 371–389.

10. Klein, R., Klein, B., E., Jensen, S., C., Mares-Perlman, J., A, et al.: Age-related maculopathy in a multiracial United States population: The National Health and Nutrition Examination Survey III. Ophthalmology 1999; 106: 1056 –1065.

11. Klein BE, Klein R, Lee KE, Moore EL, Danforth L.: Risk of incident age-related eye diseases in people with an affected sibling: The Beaver Dam Eye study. Am J Epidemiol 2001;154: 207–211.

12. Klein, R., Klein, B., E., Lee, K., E., et al.: Changes in visual acuity in a population over a 10-year period: the Beaver Dam Eye Study. Ophthalmology, 2001; 108: 1757–1766.

13. Klein, R., Klein, B., E., Wong, T., Y., et al.: The association of cataract and cataract surgery with the long-term incidence of age-related maculopathy: The Beaver Dam Eye study. Arch Ophthalmol, 2002; 120: 1551– 1558.

14. Klein, R., Klein, B., E., Tomany, S., C., et al.: Ten-year incidence and progression of age-related maculopathy: The Beaver Dam Eye study. Ophthalmology, 2002; 109: 1767–1779.

15. Klein, R., Klein, B., E., Tomany, S., C., et al.: Ten-year incidence of age-related maculopathy and smoking and drinking: The Beaver Dam Eye study. Am J Epidemiol, 2002; 156: 589 –598.

16. Klein, R., Klein, B., E., Tomany, S., C. et al.: The association of cardiovascular disease with the long-term incidence of age-related maculopathy: The Beaver Dam Eye study. Ophthalmology, 2003; 110: 1273–1280.

17. Klein., R., Peto, T., Bird, A., C., et al.: The Epidemiology of Age-Related Macular Degeneration. Am J Ophthalmol, 2004; 137: 486–495.

18. Klein, R., Klein, B., E., Lee, K., E.: Changes in Visual Acuity in a Population Over a 15-year Period: The Beaver Dam Eye Study. Am J Ophthalmol, 2006; 142: 539.e1–539.e13.

19. van Leeuwen, R., Ikram, M., K., Vingerling, J.,R., et al.: Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: The Rotterdam study. Invest Ophthalmol Vis Sci, 2003; 44: 3771–3777.

20. Mitchell, P., Smith, W., Attebo, K., et al.: Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology, 1995; 102: 1450–60.

21. Mitchell, P., Wang, J., J., Foran, S., et al.: Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology, 2002; 109: 1092–1097.

22. Roberts, J., E.: Ocular phototoxicity. J Photochem Photobiol B, 2001; 64: 136–143.

23. Rosenberg, T.: Prevalence and causes of blindness in Greenland. Arctic Med Res, 1987; 46: 13–17.

24. Rosenberg, T.: Prevalence of blindness caused by senile macular degeneration in Greenland. Arctic Med Res, 1987; 46: 64–70.

25. Sarks, S., H.: Drusen patterns predisposing to geographic atrophy of the retinal pigment epithelium. Aust J Ophthalmol, 1982; 10: 91–97.

26. Smith, W., Assink, J., Klein, R, et al.: Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001;108:697–704.

27. Sosna., T.: Epidemiologie a rizikové faktory VPMD. In Kolář, P.: Věkem podmíněná makulární degenerace, Praha: Grada, 2008, s. 148.

28. Tomany, S., C., Wang, J., J., van Leeuwen, R., et al.: Risk factors for incident age-related macular degeneration: Pooled findings from three continents. Ophthalmology, 2004; 111: 1280–1287.

29. Tong, L., Lai, M., Klein, R., et al.: Prevalence of age-related maculopathy (ARM) in a population- based cohort of adult Latinos: The Los Angeles Latino Eye Study (LALES). Invest Ophthalmol Vis Sci, 2003; 44: 2107.

30. Vingerling, J., R., Dielemans, I., Bots, M., L., et al.: Age-related macular degeneration is associated with atherosclerosis. The Rotterdam study. Am J Epidemiol, 1995; 142: 404–409.

31. Vingerling, J., R., Dielemans, I., Hofman, A., et al.: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology, 1995; 102: 205–210.

32. Wang, J., J., Foran, S., Smith, W., et al.: Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: The Blue Mountains Eye study cohort. Arch Ophthalmol, 2003; 121: 658–663.

33. Wang, J., J., Rochtchina, E., Lee, A., J., et al.: Ten-Year Incidence and Progression of Age-Related Maculopathy The Blue Mountains Eye Study. Ophthalmology, 2007; 114: 92–98.

Labels

Ophthalmology

Czech Ophthalmologic Society’s Data Collecting System for the Monitoring and Evaluating of the Exsudative Age-Related Macular Degeneration Treatment – the Nation-Wide Project “AMADEUS”

Exsudative Age-Related Macular Degeneration Treatment Results in Patients Registered in the Nation-Wide AMADEUS Register

Combined Therapy in the Exsudative Age-Related Macular Degeneration (Photodynamic Therapy and Intravitreally-Applied Ranibizumab)

Treatment of the Choroidal Neovascular Membrane by Ranibizumab (Lucentis): A Case Report

Sodium Pegaptanib and Ranibizumab in the Treatment of the Retinal Pigment Layer Ablation in a Patient with Age-Related Macular Degeneration – A Case Report

The Change of the anti-VEGF Agent in the Treatment of Exceptionally Active Choroidal Neovascular Membrane in Age-Related Macular Degeneration

Photodynamic Therapy with Verteporfin: from Neovascularization to Hemangioma

Article was published in

Czech and Slovak Ophthalmology

2010 Issue 3